New York Blood Center Enterprises (NYBCe) acquired Talaris Therapeutics, Inc.’s commercial-scale cell and gene therapy development and manufacturing facilities, as well as certain technologies and equipment from Talaris in Houston, TX and Louisville, KY.

The acquisition of both locations, combined with NYBCe’s Comprehensive Cell Solutions (CCS) cell sourcing and collection network, helps accelerate the delivery of a fully integrated vein-to-vein cell and gene therapy development and manufacturing solution in the U.S., capable of serving the biopharma industry and large hospital systems.

Both state-of-the-art facilities offer space for autologous and allogeneic cell sourcing and collection, expanding NYBCe’s collection footprint and broad donor base. The Louisville facility adds approximately 20,000 sq.-ft. with quality control and Phase 3-fitted GMP manufacturing capacity. The space provides ISO 7 cleanrooms, vast GMP capacity, cryopreservation, and storage and warehouse space, a robust digital chain of identity systems, supported by rigorous testing and release procedures.

The Houston facility offers another 6,000 sq.-ft. of analytical and process development capacity enhancing NYBCe’s expertise in broad analytical methodologies across cell types, viral vectors, mRNA, and gene expression analysis.

“I am exceptionally pleased with this strategic expansion of our CCS portfolio, which now allows NYBCe to have in-house start-to-finish cell and gene therapy, and regenerative medicine, development, and manufacturing capabilities,” said Christopher Hillyer, President, and CEO at NYBCe.  “Our new facilities and expert teams are located within key geographies, with best-in-class GMP manufacturing, and a close-to-patient transportation network as well as leading academic medical centers, which will allow us to fast-track lifesaving therapies to hospital systems.”

Mary Kay Fenton, President and Interim CEO, Talaris Therapeutics, Inc. said, “We are delighted to have this portfolio of CMC assets become a part of CCS.”